Anteby E, Yagel S, Zacut D, Palti Z, Hochner-Celnikier D
Dept. of Obstetrics and Gynecology, Hadassah-University Hospital, Mt. Scopus, Jerusalem.
Harefuah. 1993 Nov 1;125(9):267-70, 327.
Tamoxifen is an established adjuvant therapy for breast cancer. It exerts both estrogenic agonist and antagonist effects on target tissues. Since the use of tamoxifen is expanding, it is expected that more women will suffer from its side-effects. 3 women aged 48, 48, and 65, respectively, who were treated with tamoxifen, were referred for evaluation of possible side-effects. They had, respectively, endometrial hyperplasia, a unique sonographic appearance of the endometrium resembling neoplasia, and an ovarian cyst.
他莫昔芬是一种已确立的乳腺癌辅助治疗药物。它对靶组织发挥雌激素激动剂和拮抗剂的双重作用。由于他莫昔芬的使用正在扩大，预计会有更多女性遭受其副作用。分别有3名年龄为48岁、48岁和65岁的女性接受了他莫昔芬治疗，因可能出现的副作用前来接受评估。她们分别患有子宫内膜增生、子宫内膜一种类似肿瘤的独特超声表现以及卵巢囊肿。
